Effect of hepatitis C virus status on liver enzymes in opioid-dependent pregnant women maintained on opioid-agonist medication

Addiction

Volumn 107, Issue SUPPL.1, 2012, Pages 91-97

  Mcnicholas, Laura F ^a   Holbrook, Amber M ^b   O'Grady, Kevin E ^c   Jones, Hendrée E ^d,e   Coyle, Mara G ^f   Martin, Peter R ^g   Heil, Sarah H ^h,i   Stine, Susan M ^j   Kaltenbach, Karol ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RTI INTERNATIONAL   (United States)

^f BROWN UNIVERSITY   (United States)

^g VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j WAYNE STATE UNIVERSITY   (United States)

more..

Author keywords

Buprenorphine; Liver transaminases; Methadone; Opioids; Pregnancy

Indexed keywords

AMINOTRANSFERASE; BUPRENORPHINE; GAMMA GLUTAMYLTRANSFERASE; METHADONE; NARCOTIC ANALGESIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ENZYMOLOGY; FEMALE; HEPATITIS C; HUMAN; LIVER; LIVER FUNCTION TEST; METABOLISM; MULTICENTER STUDY; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREGNANCY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL MODEL;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; BUPRENORPHINE; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HEPATITIS C; HUMANS; LINEAR MODELS; LIVER; LIVER FUNCTION TESTS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PREGNANCY; PREGNANCY TRIMESTERS; TRANSAMINASES; YOUNG ADULT;

EID: 84868159985     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2012.04043.x     Document Type: Article

References (26)

1. National Institutes of Health Consensus Development Panel. Effective medical treatment of opiate addiction. JAMA 1998; 280: 1936-1943.
2. Johnson R. E., Jaffe J. H., Fudala P. J. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267: 2750-2755.
3. Ling W., Charuvastra C., Collins J. F., Batki S., Brown L. S., Kintaudi P. etal. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction 1998; 93: 475-486.
4. Mattick R. P., Ali R., White J. M., O.'Brien S., Wolk S., Danz C. Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 2003; 98: 441-452.
5. Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Comparison of buprenorphine and methadone in the treatment of opiate dependence. Am J Psychiatry 1994; 151: 1025-1030.
6. Strain E. C., Stitzer M. L., Liebson I. A., Bigelow G. E. Buprenorphine versus methadone in the treatment of opioid dependence: self reports, urinalysis, and Addiction Severity Index. J Clin Psychopharmacol 1996; 16: 58-67.
7. Johnson R. E., Chutuape M. A., Strain E. C., Walsh S. L., Stitzer M., Bigelow G. E. A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 2000; 343: 1290-1297.
8. Fudala P. J., Bridge T. P., Herbert S., Williford W. O., Chiang C. N., Jones K. etal. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 2003; 349: 949-958.
9. Jasinski D. R., Pevnick J. S., Griffith J. D. Human pharmacology and abuse potential of the analgesic buprenorphine. A potential agent for treating narcotic addiction. Arch Gen Psychiatry 1978; 35: 501-516.
10. Novick D. M., Kreek M. J., Fanizza A. M., Yancovitz S. R., Gelb A. M., Stenger R. J. Methadone disposition in patients with chronic liver disease. Clin Pharmacol Ther 1981; 30: 353-362.
11. Petry N. M., Bickel W. K., Piasecki D., Marsch L. A., Badger G. J. Elevated liver enzyme levels in opioid-dependent patients with hepatitis treated with buprenorphine. Am J Addict 2000; 9: 265-269.
12. Herve S., Riachi G., Guillement N., Tanasescu S., Goria O., Thuillez C. etal. Acute hepatitis due to buprenorphine administration. Eur J Gastroenterol Hepatol 2004; 16: 1033-1037.
13. Berson A., Gervais A., Cazals D., Boyer N., Durand F., Bernuau J. etal. Hepatitis after intravenous buprenorphine misuse in heroin addicts. J Hepatol 2001; 34: 346-350.
14. Zuin M., Giorgini A., Selmi C., Battezzati P. M., Cocchi C. A., Crosignani A. etal. Acute liver and renal failure during treatment with buprenorphine at therapeutic dose. Dig Liver Dis 2008; 41: e8-10.
15. Berson A., Fau D., Fornacciari R., Degove-Goddard P., Sutton A., Descatoire V. etal. Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 2001; 34: 261-269.
16. Abraham H., Degli-Esposti S., Marino L. Seroprevalence of hepatitis C in a sample of middle class substance abusers. J Addict Dis 1999; 18: 77-87.
17. Rosenblum A., Nuttbrock L., McQuistion H. L., Mugaru S., Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis 2001; 20: 15-25.
18. Fajemirokun-Odudeyi O., Sinha C., Tutty S., Pairaudeau P., Armstrong D., Phillips T. etal. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol 2006; 126: 170-175.
19. Ludlow J. P., Evans S. F., Hulse G. Obstetric and perinatal outcomes in pregnancies associated with illicit substance abuse. Aust NZ J Obstet Gynaecol 2004; 44: 302-306.
20. Kakko J., Heilig M., Sarman I. Buprenorphine and methadone treatment of opiate dependence during pregnancy: comparison of fetal growth and neonatal outcomes in two consecutive case series. Drug Alcohol Depend 2008; 96: 69-78.
21. Fischer G., Ortner R., Rohrmeister K., Jagsch R., Baewert A., Langer M. etal. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 2006; 101: 275-281.
22. Jones H. E., Johnson R. E., Jasinski D. R., O'Grady K. E., Chisholm C. A., Choo R. E. etal. Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 2005; 79: 1-10.
23. Gabbe S. G., Neibyl J. R., Simpson J. L. Hepatic and Gastrointestinal Diseases. In: Cappell M. S. Obstetrics: Normal and Problem Pregnancies, 5th ed. Philadelphia: Elsevier; 2007, p. 1104-1131.
24. Cunningham F. G., Leveno K. J., Bloom S., Hauth J. C., Rouse D. J., Spong C. Y. etal. Hepatic, Gallbladder and Pancreatic Disorders. In: Obstetrics, 23rd ed. New York: McGraw-Hill Medical; 2010, p. 1063-1078.
25. Jones H., Kaltenbach K., Heil S., Stine S., Coyle M., Arria A. etal. Neonatal abstinence syndrome following methadone or buprenorphine exposure. N Engl J Med 2010; 363: 2320-2331.
26. Jones H. E., Fischer G., Heil S. H., Kaltenbach K., Martin P. R., Coyle M. G. etal. Maternal Opioid Treatment: Human Experimental Research (MOTHER)-approach, issues, and lessons learned. Addiction 2012; 107 (Suppl. 1): 28-35.